Related Experiment Video
Updated: Jul 7, 2026

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice
Published on: July 5, 2024
Zingerone ameliorates ovarian impairment by regulating steroidogenesis and apoptosis in the letrozole-treated mouse
Ayushmita Dutta1, Guruswami Gurusubramanian1, Vikas Kumar Roy1
1Department of Zoology, Mizoram University, Aizawl, Mizoram 796004, India.
Abstract:
Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, disrupted folliculogenesis, and subfertility. This study evaluated the therapeutic efficacy of zingerone(4-(4-hydroxy-3-methoxyphenyl)-2-butanone) in a letrozole-induced hyperandrogenized PCOS-like mouse model. Zingerone administration, particularly at 25 and 50 mg/kg, significantly improved ovarian morphology by enhancing follicular development and corpus luteum formation. This was accompanied by increased granulosa cell proliferation and attenuation of apoptosis, evidenced by up-regulation of BCL2 and reduced terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Zingerone reprogrammed ovarian steroidogenesis by reducing circulating testosterone, down-regulating androgen receptor expression, suppressing StAR, and up-regulating aromatase, thereby promoting a shift toward estrogen biosynthesis. Autophagy analysis indicated restoration of autophagic flux, reflected by decreased p62 levels and modulation of Beclin1 and LC3B expression. These coordinated molecular and cellular changes resulted in functional recovery, with significant improvement in fertility and litter size at higher doses (25 and 50 mg/kg). Collectively, zingerone exerts dose-dependent, multitarget effects to restore endocrine, cellular, and autophagic homeostasis, thereby ameliorating ovarian dysfunction in PCOS.
Insights
Zingerone effectively treats PCOS-like symptoms in mice by improving ovarian function, restoring hormonal balance, and enhancing fertility. This natural compound offers a promising therapeutic avenue for polycystic ovary syndrome (PCOS).
Area of Science:
- Endocrinology
- Reproductive Biology
- Pharmacology
Background:
- Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology.
- Current treatments for PCOS often have limitations and side effects, necessitating the exploration of novel therapeutic agents.
Purpose of the Study:
- To investigate the therapeutic potential of zingerone, a compound found in ginger, in a letrozole-induced mouse model of PCOS.
- To elucidate the molecular mechanisms underlying zingerone's effects on ovarian function, steroidogenesis, and autophagy in PCOS.
Main Methods:
- A PCOS-like phenotype was induced in mice using letrozole.
- Mice were treated with varying doses of zingerone (25 and 50 mg/kg).
- Ovarian morphology, follicular development, granulosa cell proliferation (PCNA), apoptosis (TUNEL, BCL2), steroidogenic gene expression (StAR, aromatase), androgen receptor (AR) expression, and autophagy markers (p62, Beclin1, LC3B) were assessed.
Main Results:
- Zingerone treatment significantly improved ovarian morphology, promoting follicular development and corpus luteum formation.
- Zingerone administration attenuated apoptosis and enhanced granulosa cell proliferation.
- The compound normalized steroidogenesis by reducing testosterone, down-regulating AR, suppressing StAR, and up-regulating aromatase, leading to increased estrogen biosynthesis.
- Zingerone restored autophagic flux, indicated by decreased p62 and modulated Beclin1/LC3B.
- Fertility and litter size were significantly improved in zingerone-treated groups.
Conclusions:
- Zingerone demonstrates significant therapeutic efficacy in ameliorating PCOS-like symptoms in a mouse model.
- The multi-target actions of zingerone involve restoring endocrine, cellular, and autophagic homeostasis within the ovary.
- Zingerone represents a promising natural compound for the management of ovarian dysfunction in PCOS.
Related Concept Videos
Oogenesis
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...